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1. Siglec-H is expressed by microglia including during developmental stages in mice. 8 
2. Siglec-H expression is largely absent from other types of myeloid cells in the CNS, such as 9 
CNS-associated macrophages and CNS-infiltrating monocytes. 10 
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Abstract 1 
 Several types of myeloid cell are resident in the CNS. In the steady state, microglia 2 
are present in the CNS parenchyma, whereas macrophages reside in boundary regions of the 3 
CNS, such as perivascular spaces, the meninges and choroid plexus. In addition, monocytes 4 
infiltrate into the CNS parenchyma from circulation upon blood–brain barrier breakdown after 5 
CNS injury and inflammation. Although several markers, such as CD11b and ionized 6 
calcium-binding adapter molecule 1 (Iba1), are frequently used as microglial markers, they are 7 
also expressed by other types of myeloid cell and microglia-specific markers were not defined 8 
until recently. Previous transcriptome analyses of isolated microglia identified a transmembrane 9 
lectin, sialic acid-binding immunoglobulin-like lectin H (Siglec-H), as a molecular signature for 10 
microglia; however, this was not confirmed by histological studies in the nervous system and 11 
the reliability of Siglec-H as a microglial marker remained unclear. Here, we demonstrate that 12 
Siglec-H is an authentic marker for microglia in mice by immunohistochemistry using a 13 
Siglec-H-specific antibody. Siglec-H was expressed by parenchymal microglia from 14 
developmental stages to adulthood, and the expression was maintained in activated microglia 15 
under injury or inflammatory condition. However, Siglec-H expression was absent from 16 
CNS-associated macrophages and CNS-infiltrating monocytes, except for a minor subset of 17 
cells. We also show that the Siglech gene locus is a feasible site for specific targeting of 18 
microglia in the nervous system. In conclusion, Siglec-H is a reliable marker for microglia that 19 
will allow histological identification of microglia and microglia-specific gene manipulation in 20 
the nervous system. 21 
  22 
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Introduction 1 
 Microglia are mononuclear phagocytes in the CNS parenchyma. They originate from 2 
erythromyeloid precursors in the yolk sac and then migrate to the CNS during the embryonic 3 
stage to reside in the parenchyma (Ginhoux et al., 2010; Gomez Perdiguero et al., 2015; Hoeffel 4 
et al., 2015; Kierdorf et al., 2013; Schulz et al., 2012). Microglia play roles in various events, 5 
such as formation of neuronal circuits (Paolicelli et al., 2011; Schafer et al., 2012) and neuronal 6 
degeneration/regeneration after neuronal injury (Gamo et al., 2008; Kobayashi, Konishi, Takai, 7 
& Kiyama, 2015; Konishi, Namikawa, & Kiyama, 2006; Kroner et al., 2014). Although 8 
microglia are a well-known type of CNS myeloid cell, other types of myeloid cell also reside at 9 
the boundaries of the CNS (Galea et al., 2005; Goldmann et al., 2016; Prinz, Erny, & 10 
Hagemeyer, 2017; Prinz & Priller, 2014), including perivascular macrophages (MΦ, pvMΦ) in 11 
the perivascular space around medium- or large-sized vessels, meningeal MΦ (mMΦ) in the 12 
meninges, and choroid plexus MΦ (cpMΦ) in the choroid plexus. In addition to these 13 
“CNS-associated MΦ”, monocytes infiltrate into the CNS parenchyma from the blood 14 
circulation upon blood–brain barrier breakdown under injury or inflammatory conditions (King, 15 
Dickendesher, & Segal, 2009; Mildner et al., 2009; Saederup et al., 2010; Varvel et al., 2016). 16 
 Several molecules including CD11b and ionized calcium-binding adapter molecule 1 17 
(Iba1) were established as microglial markers, and antibodies against CD11b and Iba1 were 18 
frequently used for immunohistochemical identification of microglia (Ito et al., 1998; Robinson, 19 
White, & Mason, 1986). However, CD11b and Iba1 are widely expressed by myeloid cell types 20 
(Ajami et al., 2011; Greter, Lelios, & Croxford, 2015; Prinz & Priller, 2014; Prinz, Priller, 21 
Sisodia, & Ransohoff, 2011), meaning that the antibodies cannot discriminate microglia from 22 
CNS-associated MΦ and CNS-infiltrating monocytes by immunohistochemistry. For gene 23 
targeting of microglia, gene loci or promoter/enhancer regions of integrin subunit alpha M 24 
(Itgam) (encoding CD11b), colony-stimulating factor 1 receptor (Csf1r) and C-X3-C motif 25 
chemokine receptor 1 (Cx3cr1) were utilized (Boillee et al., 2006; Jung et al., 2000; Pfrieger & 26 
Slezak, 2012; Sasmono et al., 2003). However, microglia-specific targeting was not achieved 27 
because these genes are also expressed by other myeloid populations (Goldmann et al., 2016; 28 
Wieghofer, Knobeloch, & Prinz, 2015). Therefore identification of microglia-specific molecules, 29 
which are not expressed by other myeloid species, has been pursued. 30 
 Several studies have used transcriptome analysis to determine the molecular 31 
signature of microglia, resulting in the identification of molecules that are highly expressed by 32 
microglia but not by other myeloid cells (Bedard, Tremblay, Chernomoretz, & Vallieres, 2007; 33 
Butovsky et al., 2014; Chiu et al., 2013; Gautier et al., 2012; Hickman et al., 2013; Wes et al., 34 
2016). Among the molecules identified, the expression of transmembrane protein 119 35 
(TMEM119) (Bennett et al., 2016), Sall1 (Buttgereit et al., 2016) and P2Y12 (Mildner et al., 36 
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2017) histologically discriminated microglia from CNS-associated MΦ or CNS-infiltrating 1 
monocytes. Although expression of these molecules is restricted to microglia in the CNS, these 2 
markers are not fully specific. For example, TMEM119 expression is absent in immature 3 
microglia (Bennett et al., 2016), Sall1 is abundantly expressed in neuronal/glial progenitor cells 4 
during development (Buttgereit et al., 2016; Harrison, Nishinakamura, Jones, & Monaghan, 5 
2012), and P2Y12 shows decreased/diminished expression in activated microglia (Amadio et al., 6 
2014; Haynes et al., 2006; Mildner et al., 2017). 7 
In this study, we focused on a transmembrane lectin, sialic acid-binding 8 
immunoglobulin-like lectin H (Siglec-H), which is known as a marker for plasmacytoid 9 
dendritic cells (pDCs) in the immune system (Blasius et al., 2006; Zhang et al., 2006). Previous 10 
transcriptome and flow cytometric studies on isolated cells suggested Siglec-H as a 11 
microglia-specific molecule that was not expressed by peripheral myeloid cells, such as 12 
circulating monocytes and peripheral MΦ (Bedard, Tremblay, Chernomoretz, & Vallieres, 2007; 13 
Butovsky et al., 2014; Chiu et al., 2013; Gautier et al., 2012; Hickman et al., 2013). However, 14 
no immunohistochemical studies of the nervous system were performed, and marker specificity 15 
of Siglec-H, for instance, for CNS-associated MΦ and CNS-infiltrating monocytes, remained 16 
unexplored. Here we demonstrated microglia-specific expression of Siglec-H, including during 17 
developmental stages and under injury conditions. 18 
19 
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Materials and Methods 1 
Animals 2 
 C57BL/6J wild-type (WT) mice were purchased from Charles River Laboratories 3 
Japan. Siglech
dtr/dtr
 mice on a C57BL/6J background are described in our previous study 4 
(B6.Cg-Siglech<tm1.1Ksat> mice; deposited in RIKEN BioResource Center [accession number: 5 
RBRC05658]) (Takagi et al., 2011). Although an internal ribosome entry site (Ires)-diphtheria 6 
toxin (DT) receptor (Dtr)-enhanced green fluorescent protein (Egfp) cassette was inserted into 7 
the 3′ untranslated region of the Siglech gene in Siglechdtr/dtr mice, EGFP was not expressed in 8 
microglia in any CNS region due to unknown mechanisms (data not shown). This is consistent 9 
with the lack of EGFP expression in pDCs described in our previous study (Takagi et al., 2011). 10 
C-C chemokine receptor type 2 (Ccr2)
RFP/RFP
 knock-in mice on a C57BL/6J background were 11 
obtained from The Jackson Laboratory (stock number: 017586) (Saederup et al., 2010). 12 
Embryonic day (E)17, and male postnatal day (P)0, 7, 14, 28, and 8-12-week-old (W) (adult) 13 
mice were used. This study was approved by the local animal ethics committee of Nagoya 14 
University (approval numbers: 25107, 26181, 27204 and 28303). All experimental procedures 15 
were conducted in accordance with standard guidelines for animal experiments from the 16 
Nagoya University Graduate School of Medicine, the Animal Protection and Management Law 17 
of Japan (No. 105), and the Ethical Issues of the International Association for the Study of Pain 18 
(Zimmermann, 1983). All efforts were made to minimize the number of animals used and their 19 
suffering. 20 
 21 
Injury models 22 
Adult mice were anesthetized with isoflurane or pentobarbital for surgery. The optic 23 
nerve of Ccr2RFP/+ mice was crushed at ~1 mm from the optic disc for 5 seconds using fine 24 
forceps, and analyzed by immunohistochemistry 7 days after injury. Experimental autoimmune 25 
encephalomyelitis (EAE) was induced by immunizing Ccr2
RFP/+
 mice with MOG35–55 peptide 26 
followed by injection of pertussis toxin as previously described (Bando et al., 2015). After the 27 
appearance of hindlimb paralysis, the ventral white matter of the L4 spinal cord was analyzed 28 
by immunohistochemistry. The sciatic nerve was unilaterally transected using scissors and, 7 29 
days after surgery, the sciatic nerve and spinal dorsal horn were analyzed by 30 
immunohistochemistry and quantitative real-time PCR (qPCR). For a neuropathic pain model, 31 
the spinal L4 nerve of WT and Siglechdtr/dtr mice was unilaterally transected using scissors 32 
according to our method described previously (Kobayashi et al., 2016), and pain testing, 33 
immunohistochemistry and qRT-PCR were performed 1, 3, 7 and 14 days after surgery. 34 
 35 
Ablation of microglia 36 
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DT (50 µg/kg) (Sigma Aldrich) was intraperitoneally administrated to P7 or adult 1 
Siglech
dtr/dtr
 mice. For the nerve-injury model, the sciatic nerve of adult Siglech
dtr/dtr
 mice was 2 
unilaterally transected 7 days before DT administration. Brains, spinal cords and sciatic nerves 3 
were processed for immunohistochemistry 2 days after DT administration. 4 
 5 
Immunohistochemistry 6 
Immunohistochemistry was performed according to our previously described method 7 
with slight modification (Konishi et al., 2007). Mice were perfused with Zamboni’s fixative (0.1 8 
M phosphate buffer containing 2% paraformaldehyde and 0.2% picric acid), and then brains, the 9 
L4 level of spinal cords, optic and sciatic nerves were dissected. Post-fixation was avoided in 10 
this study because over-fixation significantly decreased the immunoreactivity of Siglec-H. The 11 
brains of E17 mice and spinal cords of adult EAE model mice were fixed by immersion in 12 
Zamboni’s fixative for 4–6 h at 4°C. Tissues were dehydrated in 25% sucrose in 0.1 M 13 
phosphate buffer overnight at 4°C and then frozen in dry ice. Floating or slide-mounted sections 14 
were cut on a microtome at 16 or 30 µm, washed in 0.01 M phosphate buffered saline (PBS), 15 
and then reacted with primary antibodies diluted in a blocking solution (0.01 M PBS containing 16 
1% bovine serum albumin, 0.1% Triton X100 and 0.1% NaN3). The following primary 17 
antibodies were used: rabbit polyclonal anti-Iba1 (WAKO #019-19741, RRID: AB_839504), 18 
goat polyclonal anti-Iba1 (Abcam #ab5076, RRID: AB_2224402), rat monoclonal anti-CD206 19 
(Bio-rad #MCA2235GA, RRID: AB_322613), goat polyclonal anti-CD206 (R&D systems 20 
#AF2535, RRID: AB_2063012), rabbit polyclonal anti-laminin (Abcam #ab11575, RRID: 21 
AB_298179), and rabbit polyclonal anti-protein kinase C gamma (PKCγ) (Santa Cruz 22 
Biotechnology #sc-211, RRID: AB_632234). Characterization of the polyclonal anti-Siglec-H 23 
antibody used in the present study was described in our previous study (Zhang et al., 2006). 24 
Briefly, a sheep was immunized with the extracellular domain of mouse Siglec-H fused with Fc 25 
region of human IgG (Fc) (Siglec-H-Fc), and anti-Siglec-H antibody was purified by affinity 26 
chromatography using Siglec-H-Fc-coupled column. For antigen absorption tests, anti-Siglec-H 27 
antibody was reacted with 1.0 µM of the Fc, Siglec-H-Fc or Siglec-E-Fc (Biolegend) in 0.01M 28 
PBS overnight at 4°C. The reaction mixture was centrifuged at 10,000g for 20 min at 4°C, and 29 
then the supernatant was used as the primary antibody solution. After reaction with primary 30 
antibodies, sections were washed in 0.01 M PBS, and reacted with secondary antibodies 31 
conjugated with Alexa Fluor 488, 594 or 647 (Thermo Fisher Scientific). After washing in 0.01 32 
M PBS, sections were mounted with FluorSave reagent (Merck Millipore). Images were taken 33 
using an FV10i confocal microscope (Olympus). 34 
 35 
Quantitative histological analysis 36 
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Rate of Siglec-H
+
 microglia in the cerebral cortex: In adult mice, we defined 1 
parenchymal Iba1
+
 cells with ramified morphology as microglia, and quantified the rate of 2 
Siglec-H
+
 microglia in the cerebral cortex, corpus callosum, hippocampal CA1 area, ventral 3 
posterolateral/posteromedial thalamic nucleus, cerebellar cortex, spinal trigeminal nucleus of 4 
the medulla, and the dorsal horn of the spinal cord in Iba1 stained sections. In contrast to adult 5 
mice, microglia were not fully ramified in embryonic and early postnatal mice, and could not be 6 
clearly distinguished from pvMΦ by Iba1 immunostaining. We therefore calculated the 7 
Siglec-H+ rate against all Iba1+ cells in the cerebral cortex under the meninges in E17, P0 and 8 
P7 mice. A total of 36 images (3 fields/section, 3 sections/animal, 4 animals) were analyzed. 9 
Rate of Siglec-H
+
 pvMΦ or mMΦ in the cerebral cortex: We calculated the Siglec-H
+
 10 
rate of CD206
+
 pvMΦ or mMΦ in the cerebral cortex of adult mice. A total of 36 images (3 11 
fields/section, 3 sections/animal, 4 animals) were analyzed. 12 
Rate of Siglec-H+ microglia and circumventricular organ MΦ (cvoMΦ) in the area 13 
postrema: We calculated the Siglec-H+ rate of Iba1+/CD206– microglia or cvoMΦ in the area 14 
postrema of adult mice. A total of 12 images (1 field/section, 3 sections/animal, 4 animals) were 15 
analyzed. 16 
Percentage of three different populations of Iba1
+
 cells in the choroid plexus: We 17 
calculated the percentage of Siglec-H
+
/CD206
–
, Siglec-H
–
/CD206
+
 and Siglec-H
+
/CD206
+
 cells 18 
against total Iba1
+
 cells in the choroid plexus of lateral ventricle of adult mice. A total of 12 19 
images (1 field/section, 3 sections/animal, 4 animals) were analyzed. 20 
 Rate of Siglec-H+ monocytes in the EAE model: The ventral white matter of the L4 21 
spinal cord in Ccr2RFP/+ mice with EAE was analyzed. Sections were stained with anti-Siglec-H 22 
antibody, and the Siglec-H+ rate in RFP+ infiltrating monocytes was calculated. A total of 45 23 
images (3 fields/section, 3 sections/animal, 5 animals) were analyzed. 24 
 Rate of microglia and MΦ ablation: Sections were prepared form the cerebral cortex 25 
and medulla (for the area postrema) of non-injured adult Siglech
dtr/dtr
 mice 2 days after DT 26 
administration, and double-stained with anti-Iba1 and anti-CD206 antibodies. We defined 27 
Iba1
+
/CD206
–
 and Iba1
+
/CD206
+
 cells as microglia and MΦ, respectively, and counted cell 28 
numbers in 12 images (1 field/section, 4 sections/animal, 3 animals). For the nerve injury model, 29 
sections of L4 spinal cord dorsal horn and sciatic nerve were prepared from sciatic 30 
nerve-injured adult Siglechdtr/dtr mice 2 days after DT administration. Spinal sections were 31 
immunoreacted with anti-Iba1 and anti-PKCγ antibodies to stain microglia and the inner lamina 32 
II of the dorsal horn (Malmberg, Chen, Tonegawa, & Basbaum, 1997), respectively. The number 33 
of Iba1
+
 cells in lamina I and outer lamina II (I/IIo) was counted and is shown as microglial 34 
numbers because pvMΦ were rare and their numbers were negligible in the dorsal horn. The 35 
sciatic nerve was stained with anti-Iba1 antibody to identify monocytes/MΦ. Images taken by a 36 
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confocal microscope were acquired using the same laser power and sensitivity, and Iba1
+
 areas 1 
were measured using Image J software version 10.2 (NIH, RRID: SCR_003070). A total of 12 2 
images (1 field/section, 4 sections/animal, 3 animals) were analyzed. For developmental stages, 3 
DT was administrated to P7 Siglech
dtr/dtr
 mice. Sections of the cerebral cortex were prepared 4 
after 2 days, and were stained with anti-Iba1 antibody. CD206 immunostaining was not 5 
performed because pvMΦ and mMΦ could not be distinguished from microglia by CD206 6 
immunoreactivity. We counted the number of Iba1+ cells in the cerebral cortex beneath the 7 
meninges in a total of 12 images (1 field/section, 4 sections/animal, 3 animals). 8 
 Number of microglia in the dorsal horn of the neuropathic pain model: Adult WT and 9 
Siglech
dtr/dtr
 L4 spinal cord sections were prepared 7 days after L4 nerve transection. Sections 10 
were stained with anti-Iba1 and anti-PKCγ antibodies, and the number of Iba1
+
 cells in the 11 
lamina I/IIo of the dorsal horn was counted. A total of 16 images (1 field/section, 4 12 
sections/animal, 4 animals) were analyzed. 13 
 14 
qPCR 15 
 Cerebral cortex was collected from E17, P0, P7, P14, P28 and 8W WT, and 8W 16 
Siglech
dtr/dtr
 mice (n = 3). L4 spinal dorsal horn and sciatic nerve were taken from WT mice 7 17 
days after sciatic nerve transection (n = 3). L4 spinal dorsal horn was dissected from WT and 18 
Siglech
dtr/dtr
 mice, 0 (naive), 1, 3, 7 and 14 days after L4 nerve transection (n = 3). mRNA was 19 
purified from tissues using the acid guanidine iso-thiocyanate/phenol/chloroform extraction 20 
method, and converted to cDNA by SuperScript III (Thermo Fisher Scientific). qPCR was 21 
performed using StepOnePlus (Applied Biosystems) with Fast SYBR Green Master Mix 22 
(Applied Biosystems): 1 cycle of 95°C for 20 s, 40 cycles of 95°C for 3 s, and 60°C for 30 s. 23 
Primers were as follows; glyceraldehyde-3-phosphate dehydrogenase (Gapdh) (sense 24 
5′-TGACGTGCCGCCTGGAGAAA-3′, antisense 25 
5′-AGTGTAGCCCAAGATGCCCTTCAG-3′), Siglech (sense 26 
5′-TGGTACAGGTAGCCATGGGA-3′, antisense 5′-TGTGTTGCTGGTCTCTCCAC-3′), 27 
allograft inflammatory factor 1 (Aif1) (gene encoding Iba1) (sense 28 
5′-GGATCTGCCGTCCAAAC-3′, antisense 5′-GCATTCGCTTCAAGGACA-3′), tumor 29 
necrosis factor (TNF)-α (Tnfa) (sense 5′-GTGGAACTGGCAGAAGAGGC-3′, antisense 30 
5′-AGACAGAAGAGCGTGGTGGC-3′), interleukin (IL)-1β (Il1b) (sense 31 
5′-CTGTGTCTTTCCCGTGGACC-3′, antisense 5′-CAGCTCATATGGGTCCGACA-3′), Il10 32 
(sense 5′-GGTTGCCAAGCCTTATCGGA-3′, antisense 5′-ACCTGCTCCACTGCCTTGCT-3′), 33 
and transforming growth factor (TGF)-β1 (Tgfb1) (sense 34 
5′-CCGCAACAACGCCATCTATG-3′, antisense 5′-TGCCGTACAACTCCAGTGAC-3′). 35 
Amplified PCR samples were subjected to melting analysis to confirm amplicon specificity. 36 
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Results were normalized to Gapdh and analyzed using the 2−∆Ct method. 1 
 2 
Behavioral analysis of neuropathic pain 3 
WT and Siglech
dtr/dtr
 mice, 0, 3, 7 and 14 days post L4 spinal nerve transection were 4 
analyzed (n = 4). Mice were individually placed in an opaque chamber with a wire mesh floor. 5 
After habituation at least for 30 min, the tip of an Electronic von Frey Anesthesiometer (IITC 6 
Life Science) was applied to the plantar surfaces of their hindpaws and the paw withdrawal 7 
threshold (PWT) was measured. 8 
 9 
Statistical analysis 10 
 All values are expressed as the mean ± S.E.M. Changes in gene expression and cell 11 
numbers were analyzed with the unpaired Student’s t-test. PWT data was analyzed by two-way 12 
ANOVA with a post hoc Bonferroni test. p < 0.05 was considered statistically significant. 13 
  14 
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Results 1 
Siglec-H is specifically expressed by microglia in the steady state CNS of adult mice, 2 
except for in the choroid plexus 3 
We stained sections of cerebral cortex prepared from adult mice with a polyclonal 4 
antibody against Siglec-H (Figure 1) (Zhang et al., 2006). Clear signals were observed in Iba1+ 5 
microglia with ramified morphologies in the parenchyma (Figure 1a–c). The signals 6 
disappeared after absorption of the antibody with antigen (Siglec-H-Fc) (Figure 1d–f), 7 
suggesting the antibody-antigen specificity. Because Siglec-E was also shown as a microglial 8 
signature gene among Siglec family members in mice (Bennett et al., 2016; Claude et al., 2013; 9 
Hickman et al., 2013), we confirmed that the Siglec-H antibody did not cross-react with 10 
Siglec-E (Figure 1g–i). The antibody-antigen specificity was further confirmed using Siglech 11 
knock-down mice. In Siglech
dtr/dtr
 mice, an Ires and the gene encoding the DT receptor were 12 
knocked into the 3′ untranslated region of the Siglech gene (Takagi et al., 2016; Takagi et al., 13 
2011). This genetic modification was not expected to affect the expression of Siglech; however, 14 
our previous study found that Siglec-H expression was knocked-down in pDCs in the immune 15 
system of Siglechdtr/dtr mice. qPCR showed that levels of Siglech mRNA were knocked-down in 16 
the cerebral cortex of Siglech
dtr/dtr
 mice (75.1% decrease compared with WT by qPCR, n = 3, p < 17 
5.0 × 10
-6
). In line with the downregulation of mRNA, microglial Siglec-H immunoreactivity 18 
was significantly lower in Siglech
dtr/dtr
 mice compared with WT (Figure 1j–o), demonstrating 19 
antibody-antigen specificity of the Siglec-H antibody in immunohistochemistry. 20 
In cortical sections, CD206+ pvMΦ were found along medium- or large-sized vessels 21 
but not along capillaries (single arrowheads in Figure 2b), and CD206+ mMΦ were found in the 22 
meninges (double arrowheads in Figure 2b) (Galea et al., 2005; Goldmann et al., 2016). These 23 
two types of macrophages had spindle or round shapes with fewer processes compared with 24 
parenchymal microglia (Figure 2b) and were almost negative for Siglec-H (Figure 2a; Siglec-H
+
 25 
pvMΦ: 1.7 ± 0.6%; Siglec-H
+
 mMΦ: 0.3 ± 0.3%), whereas parenchymal ramified microglia 26 
were positive in the same sections (arrows in Figure 2a). In contrast to the microglia-specific 27 
expression of Siglec-H, Iba1 was expressed by all myeloid cells in cortical sections (Siglec-H
+
 28 
microglia, CD206+ pvMΦ and CD206+ mMΦ) (Figure 2e–h). Circumventricular organs are 29 
brain areas lacking the blood–brain barrier (Kaur & Ling, 2017; Morita & Miyata, 2012). 30 
Sensory circumventricular organs, such as the ‘area postrema’ in the dorsal medulla, contain a 31 
large number of MΦ around capillaries (Goehler, Erisir, & Gaykema, 2006; Murabe, Nishida, & 32 
Sano, 1981; Willis, Garwood, & Ray, 2007). We defined MΦ within circumventricular organs as 33 
circumventricular organ MΦ (cvoMΦ) in this study because cvoMΦ are different from pvMΦ in 34 
that cvoMΦ contact capillaries and are assumed to play specific roles, such as forming a 35 
size-selective diffusion barrier around capillaries in circumventricular organs (Goehler, Erisir, & 36 
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Gaykema, 2006; Murabe, Nishida, & Sano, 1981; Willis, Garwood, & Ray, 2007). In the area 1 
postrema, Siglec-H was not detected in Iba1
+
/CD206
+
 cvoMΦ with few processes (arrowheads 2 
in the inset of Figure 2i–l); however, Siglec-H was expressed by putative Iba1
+
/CD206
–
 3 
microglia with ramified shapes (an arrow in the inset of Figure 2i–l; Siglec-H
+
 rate of 4 
Iba1+/CD206– cells: 96.4 ± 0.9%), except for a minor Iba1+ population that expressed both 5 
Siglec-H and CD206 (an asterisk in Figure 2i–l; 3.6 ± 0.9% of Iba1+/Siglec-H+ cells; 3.2 ± 0.7% 6 
of Iba1+/CD206+ cvoMΦ). We obtained the same results in another sensory circumventricular 7 
organ, the ‘subfornical organ’ at the roof of the third ventricle (data not shown). In contrast to 8 
the cerebral cortex and sensory circumventricular organs, results were different in the choroid 9 
plexus (Figure 2m–p), which is known to contain cpMΦ with a higher turnover rate compared 10 
with mMΦ and pvMΦ (Goldmann et al., 2016). In addition to Siglec-H
+
/CD206
–
 (an arrow in 11 
Figure 2m–p; 17.5 ± 3.0% of total Iba1
+
 cells) and Siglec-H
–
/CD206
+
 cells (arrowheads in 12 
Figure 2m–p; 60.3 ± 4.5% of total Iba1+ cells), Siglec-H+/CD206+ cells were also frequently 13 
observed (asterisks in Figure 2m–p; 11.5 ± 2.0% of total Iba1+ cells; 40.0 ± 6.3% of 14 
Iba1+/Siglec-H+ cells; 16.2 ± 2.7% of Iba1+/CD206+ cells). 15 
Microglia-specific Siglec-H expression was also examined in the parenchyma of 16 
representative CNS regions, including hippocampal CA1 (Supporting Information Figure S1a–17 
c) and the white matter (corpus callosum) (Supporting Information Figure S1d–f). The rate of 18 
Siglec-H
+
 microglia with respect to Iba1
+
 cells with ramified morphologies in the parenchyma 19 
was almost 100% in all regions examined (cerebral cortex: 100.0%; corpus callosum: 100.0%; 20 
hippocampus: 99.7 ± 0.3%; thalamus: 100.0%; cerebellum: 99.8 ± 0.2%; medulla: 100.0%; 21 
spinal cord: 100.0%) (Supporting Information Figure S1g), and all Siglec-H+ cells were Iba1+. 22 
These results demonstrated that Siglec-H expression was confined to microglia in the steady 23 
state CNS except for in the choroid plexus. 24 
 25 
Siglec-H is specifically expressed by microglia in the developing CNS 26 
 The recently identified microglia-specific markers, TMEM119 and Sall1, are not 27 
specific during mouse development (Bennett et al., 2016; Buttgereit et al., 2016; Harrison, 28 
Nishinakamura, Jones, & Monaghan, 2012); therefore, we tested whether Siglec-H is specific 29 
for microglia during development (Figure 3). Even though microglial numbers in the cerebral 30 
cortex were small at E17 (Swinnen et al., 2013), Siglech mRNA was clearly detected by qPCR 31 
at a similar level to Aif1 mRNA (encoding Iba1) (Figure 3a). Because microglia express Iba1 32 
from an early developmental stage (Hirasawa et al., 2005), we expected that Siglec-H 33 
immunoreactivity could be detected in embryonic microglia by immunohistochemistry. In 34 
embryonic mice, it was difficult to immunohistochemically distinguish microglia from mMΦ or 35 
pvMΦ, because immature microglia also expressed CD206 (data not shown) and were not fully 36 
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ramified. Although microglia could not be defined clearly by morphology at E17, Siglec-H 1 
expression was observed in putative Iba1
+
 microglia in parenchyma, but not in some Iba1
+
 cells 2 
in the meninges, which might correspond to mMΦ (Figure 3b–d). At P7, microglial ramification 3 
proceeded and microglia were distinguishable from mMΦ and pvMΦ by their morphologies 4 
(Figure 3f). Siglec-H was detected in ramified microglia in parenchyma whereas putative mMΦ, 5 
which had large cell bodies with few processes, were negative for Siglec-H (Figure 3e–g). A 6 
quantitative study showed that Siglec-H was expressed by most Iba1+ cells during development 7 
(E17: 96.4 ± 0.6%; P0: 95.5 ± 0.7%; P7: 98.5 ± 1.0%; relative to all Iba1+ cells in the cerebral 8 
cortex beneath the meninges) (Figure 3h). 9 
 10 
Siglec-H is not expressed by monocytes infiltrating an injured or inflamed nervous system 11 
 Circulating CCR2
+
 monocytes can enter the nervous system upon neuronal injury or 12 
inflammation, and play distinct roles from those of microglia (King, Dickendesher, & Segal, 13 
2009; Mildner et al., 2009; Varvel et al., 2016; Yamasaki et al., 2014). We hypothesized that 14 
Siglec-H expression could discriminate resident microglia from infiltrating monocytes, and 15 
examined the possibility using an optic nerve injury model (Figure 4a–h). We used Ccr2RFP/+ 16 
mice, in which monocytes infiltrating the CNS are labeled with red fluorescent protein (RFP) 17 
(Saederup et al., 2010). Siglec-H expression was observed in Iba1
+
 microglia with elongated 18 
morphology along the axons of the control optic nerve, and no RFP
+
 monocytes were found 19 
(Figure 4a–d). In contrast, a significant number of RFP
+
 monocytes with a round or spindle 20 
shape had invaded the injured optic nerve 7 days after crush injury (Figure 4f), and these RFP+ 21 
monocytes were negative for Siglec-H (Figure 4e–h). We could not perform a quantitative study 22 
of Siglec-H+ monocytes because the monocyte density was high and counting monocyte 23 
numbers was difficult (Figure 4f). 24 
We also tested an inflammatory model of the CNS (Figure 4i–p). We immunized 25 
Ccr2
RFP/+
 mice with MOG peptide to induce EAE. After hindlimb paralysis appeared, the spinal 26 
cord was dissected and processed for immunohistochemistry. In contrast to control mice (Figure 27 
4j), RFP
+
 monocytes with round or spindle shapes were infiltrated into the white matter of mice 28 
with EAE (Figure 4n). While activated Iba1+ microglia with hypertrophic morphology 29 
expressed Siglec-H, infiltrating monocytes were negative for Siglec-H (Figure 4m–p), except 30 
for a minor population that markedly expressed Siglec-H compared with resident microglia (an 31 
asterisk in Figure 4m–p; 1.8 ± 0.3% of total RFP+ cells). 32 
In addition to the CNS, we examined the PNS. Peripheral nerve injury causes 33 
accumulation of MΦ in the distal part of the injured nerve, which is necessary for Wallerian 34 
degeneration (Chen, Piao, & Bonaldo, 2015). Although resident MΦ in peripheral nerves 35 
proliferate and contribute to the pool, the main source of accumulated MΦ is monocytes 36 
Page 13 of 41
John Wiley & Sons, Inc.
GLIA
 14 
recruited from the circulation (Beuche & Friede, 1984). Thus we examined whether monocytes 1 
infiltrating the injured peripheral nerve express Siglec-H (Figure 5). The nerve injury caused 2 
accumulation of microglia and monocytes/MΦ in the ipsilateral spinal cord (Figure 5b,e) and 3 
injured nerve (Figure 5h), respectively, 7 days after sciatic nerve transection. Although Siglec-H 4 
was expressed by Iba1+-activated microglia in the dorsal horn (Figure 5a–f), Siglec-H 5 
expression was not detected in Iba1+ monocytes/MΦ in the injured sciatic nerve (Figure 5g–i). 6 
These histological data were confirmed by qPCR (Figure 5j,k). Siglec-H expression was 7 
increased concomitantly with Iba1 induction in the dorsal horn after injury (Figure 5j). In 8 
contrast, Siglec-H expression was not induced in the injured nerve although Iba1 expression 9 
was markedly increased (Figure 5k). 10 
 Collectively, Siglec-H can be used as a histological marker that distinguishes resident 11 
microglia from infiltrating monocytes both in the CNS and PNS, except for a minor population. 12 
 13 
The Siglech locus is suitable for microglia-specific gene targeting 14 
Our histological analyses indicated Siglec-H to be a microglia-specific marker in the 15 
nervous system, which prompted us to explore the suitability of the Siglech locus for 16 
microglia-specific gene targeting in mice (Figure 6). To this end, we used Siglech
dtr/dtr
 mice, in 17 
which Siglec-H
+
 cells express the DT receptor and can be ablated by systemic DT 18 
administration (Takagi et al., 2011). After peritoneal injection of DT into adult Siglech
dtr/dtr
 mice, 19 
a significant number of microglia in the cerebral cortex was ablated within 2 days (Figure 6a,b). 20 
The number of Iba1+/CD206– microglia decreased to 20.6% (Figure 6c), while those of CD206+ 21 
pvMΦ and mMΦ were unchanged (Figure 6d,e). We also demonstrated in the area postrema that 22 
DT was ineffective at ablating CD206+ cvoMΦ in contrast to Iba1+/CD206– microglia (85.8% 23 
decrease in DT-administrated group) (Figure 6f–i).  24 
We also demonstrated that Siglech locus-mediated gene targeting had no effects on 25 
infiltrating monocytes. We prepared adult Siglech
dtr/dtr
 mice with sciatic nerve injury and 7 days 26 
after surgery DT was administered to the mice and cell ablation rates calculated (Figure 6j–o). 27 
For microglia in the dorsal horn, we counted the number of parenchymal Iba1
+
 cells without 28 
CD206 staining because pvMΦ were rare and their number was negligible in the dorsal horn. In 29 
lamina I and outer II (I/IIo) of the dorsal horn, which was defined by visualizing inner lamina II 30 
by PKCγ immunostaining (Malmberg, Chen, Tonegawa, & Basbaum, 1997), microglial 31 
numbers were significantly reduced both in the contralateral and ipsilateral side, 2 days after DT 32 
administration (contralateral side: 76.6% decrease in DT-administrated group; ipsilateral side: 33 
78.9% decrease in DT-administrated group) (Fig. 6j–l). By contrast, the number of 34 
monocytes/MΦ in the sciatic nerve was unchanged (Figure 6m–o). Taken together, these results 35 
indicate that the Siglech locus is suitable for microglia-specific gene targeting in adult mice 36 
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without affecting the behavior of CNS-associated MΦ, such as pvMΦ, mMΦ and cvoMΦ, and 1 
infiltrating monocytes in the nervous system. 2 
 A hallmark of Siglec-H was its expression in immature microglia (Figure 3); 3 
therefore, we administrated DT to P7 Siglech
dtr/dtr
 mice and analyzed the cerebral cortex at P9 4 
(Figure 6p–r). Similar to E17 (Figure 3b–d) and P7 (Figure 3e–g) mice, pvMΦ and mMΦ could 5 
not be distinguished from microglia by CD206 immunoreactivity at P9 (data not shown). Thus 6 
we stained laminin to visualize vessels and meninges (Figure 6p,q). Most Iba1+ ramified 7 
microglia were ablated within 2 days of DT administration. In contrast, Iba1+ cells with large 8 
cell bodies and few processes, located in the perivascular region (putative pvMΦ indicated by 9 
single arrowheads in Figure 6p,q) and meninges (putative mMΦ indicated by double 10 
arrowheads in Figure 6p,q), were unaffected. Statistical analysis showed a 91.9% decrease of 11 
Iba1
+
 cells in the cerebral cortex beneath the meninges in the DT-administrated group (Figure 12 
6r). It should be noted that most of the remaining Iba1+ cells (8.1%) were putative pvMΦ along 13 
the vessels, and that almost all the microglia were ablated in the parenchyma. 14 
 15 
Siglec-H suppressed inflammatory responses of activated microglia 16 
Finally we addressed Siglec-H function using a mouse neuropathic pain model. In 17 
this model, transection of the L4 spinal nerve induces microglial activation in the L4 dorsal horn, 18 
and the resulting inflammatory responses of activated microglia develop and prolong 19 
neuropathic pain (Tsuda, 2016). In the ipsilateral dorsal horn of the model mice, expression of 20 
Siglech mRNA increased after injury with a peak at 3 days (Figure 7a), when the microglial 21 
numbers also reached a peak (Kobayashi et al., 2016). Siglech mRNA was significantly 22 
decreased in the ipsilateral dorsal horn of Siglechdtr/dtr mice compared with WT (Figure 7a). 23 
Immunohistochemistry demonstrated that Siglec-H protein was expressed in activated Iba1+ 24 
microglia in the ipsilateral dorsal horn of WT mice (Figure 7b–g). However, Siglec-H 25 
immunoreactivity was very low in Siglech
dtr/dtr
 mice (Figure 7h–j). Thus we assumed that 26 
Siglec-H could be functionally impaired in Siglech
dtr/dtr
 mice, and we analyzed the functional 27 
consequences of Siglech impairment in the pain model. qPCR showed that the nerve injury 28 
induced the expression of representative pro-inflammatory cytokines, Tnfa and Il1b, in the 29 
ipsilateral dorsal horn (Figure 7k) (Tsuda, 2016). Siglech knock-down increased the expression 30 
of Tnfa and Il1b but did not affect expression of anti-inflammatory cytokines, such as Il10 and 31 
Tgfb1. Because the ipsilateral dorsal horn of WT and Siglechdtr/dtr mice contained almost equal 32 
numbers of microglia (1.03-fold increase in Siglech
dtr/dtr
 compared with WT mice at 7 days) 33 
(Figure 7l–n), the increase in Tnfa and Il1b mRNA observed in Siglech
dtr/dtr
 mice was likely the 34 
result of upregulation of gene expression in microglia. Lastly, we evaluated mechanical 35 
allodynia in Siglech
dtr/dtr
 mice using the von Frey test (Figure 7o,p). Although PWT of the 36 
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contralateral side was comparable between WT and Siglech
dtr/dtr
 mice (Figure 7o), that of the 1 
ipsilateral side was lower in Siglech
dtr/dtr
 mice after nerve injury with significant differences at 2 
day 3 (Figure 7p), demonstrating that mechanical allodynia was exacerbated in Siglech
dtr/dtr
 mice. 3 
These results suggest that Siglec-H suppresses the pro-inflammatory response of microglia, 4 
reducing neuropathic pain. 5 
6 
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Discussion 1 
 In this study, we explored the feasibility of Siglec-H as a specific marker for 2 
microglia in the nervous system. We revealed that almost all microglia in the CNS parenchyma 3 
expressed Siglec-H, from developmental to mature stages (Figures 1–3; Supporting Information 4 
Figure S1), and the expression was maintained in activated microglia after CNS (Figure 4) and 5 
PNS injuries (Figures 5 and 7a–g). In contrast, Siglec-H expression was largely absent from 6 
other myeloid cells in the nervous system: CNS-associated MΦ (pvMΦ, mMΦ and cvoMΦ; 7 
Figure 2), and monocytes infiltrating into the CNS (Figure 4) and PNS (Figure 5). On the basis 8 
of the Siglec-H expression profile, we further demonstrated the use of the Siglech locus for 9 
microglia-specific gene manipulation in both mature and developing mice (Figure 6). 10 
Collectively, we conclude that Siglec-H is a specific marker that will be highly useful for 11 
microglial studies. 12 
 Siglec-H is a single-pass transmembrane protein belonging to the CD33-related 13 
Siglec family (Macauley, Crocker, & Paulson, 2014). Although there are no clear orthologs in 14 
human, Siglec-L2 is ~42% homologous and is assumed to be a potential ortholog (Zhang et al., 15 
2006). Siglec-H is known as a marker for pDCs in the immune system (Blasius et al., 2006; 16 
Takagi et al., 2011; Zhang et al., 2006). Several previous studies employing transcriptome or 17 
flow cytometric analyses using isolated cells suggested that Siglec-H was abundantly expressed 18 
in microglia compared with peripheral myeloid cells, such as circulating monocytes and 19 
peripheral MΦ (Bedard, Tremblay, Chernomoretz, & Vallieres, 2007; Butovsky et al., 2014; 20 
Chiu et al., 2013; Gautier et al., 2012; Hickman et al., 2013). However, no 21 
immunohistochemical studies were performed in the nervous system, and it remained unknown 22 
whether Siglec-H was expressed by CNS-associated MΦ as well as monocytes infiltrating in the 23 
nervous system. In this study, we demonstrated that Siglec-H expression was largely confined to 24 
microglia (Figures 1–5; Supporting Information Figure S1) by using a Siglec-H-specific 25 
antibody (Zhang et al., 2006), whose antigen-specificity was confirmed by an absorption test 26 
(Figure 1d–i) and by the use of Siglech knock-down mice (Figures 1m–o and 7h–j). Several 27 
marker antibodies such as Iba1 and CD11b are frequently used for immunohistochemical 28 
detection of microglia; however, these molecules are also expressed by CNS-associated MΦ in 29 
the steady state (Figure 2) as well as by infiltrating monocytes in the injured nervous system 30 
(Figure 4e–h and 5g–i) (Greter, Lelios, & Croxford, 2015; Prinz & Priller, 2014; Prinz, Priller, 31 
Sisodia, & Ransohoff, 2011). This broader expression makes it difficult to discriminate 32 
microglia from other myeloid cells by immunohistochemistry. In addition to these classical 33 
markers, Bennette et al. (Bennett et al., 2016) recently reported a transmembrane protein, 34 
TMEM119, as a microglia-specific marker, for which mMΦ, pvMΦ and cpMΦ, and 35 
CNS-infiltrating monocytes were negative. Although the authors demonstrated specificity of 36 
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TMEM119 expression in microglia, the expression was very low or absent in immature 1 
microglia in embryonic and early postnatal mice. Sall1 has also recently been shown to be a 2 
microglia-specific transcription factor using Sall1
GFP
 and Sall1
CreER
 knock-in mice (Buttgereit et 3 
al., 2016; Koso et al., 2016). Sall1 expression was highly restricted to microglia in the CNS of 4 
adult mice; however, Sall1 expression was abundantly observed in neuronal/glial progenitor 5 
cells in embryonic mice (Buttgereit et al., 2016; Harrison, Nishinakamura, Jones, & Monaghan, 6 
2012). This is in contrast to Siglec-H because Siglec-H expression was observed in microglia in 7 
embryonic and early postnatal mice (Figure 3). More recently, Mildner et al. (Mildner et al., 8 
2017) reported that a purinoceptor, P2Y12, is detected in microglia but not in pvMΦ and mMΦ 9 
in the developing human brain. Additionally, previous reports showed that P2Y12 expression 10 
was detected in microglia but not in splenic MΦ or CNS-infiltrating monocytes by 11 
immunohistochemistry in mice (Butovsky et al., 2014; Haynes et al., 2006). However, P2Y12 12 
expression is significantly decreased or diminished in activated microglia (Amadio et al., 2014; 13 
Haynes et al., 2006; Mildner et al., 2017), whereas Siglec-H expression was maintained in 14 
microglia activated by CNS (Figure 4) and PNS injuries (Figures 5 and 7b–g). 15 
 In addition to microglia, Siglec-H was detected in Iba1+ cells in the choroid plexus 16 
(Figure 2m–p). Iba1
+
 cells in the choroid plexus can be divided into three subsets: 17 
Siglec-H
+
/CD206
–
 (an arrow in Figure 2m–p), Siglec-H
–
/CD206
+
 (arrowheads) and 18 
Siglec-H
+
/CD206
+
 (asterisks) cells. This suggests that cpMΦ consists of heterogeneous 19 
populations in contrast to pvMΦ, mMΦ and cvoMΦ. A recent paper revealed the heterogeneity 20 
of cpMΦ (Goldmann et al., 2016). The authors showed that cpMΦ, pvMΦ and mMΦ were all 21 
derived from precursors in the yolk sac and/or the fetal liver. However, cpMΦ have a shorter life 22 
span and are gradually replenished by circulating myeloid cells, while pvMΦ and mMΦ persist 23 
throughout life. Subpopulation(s) of cpMΦ can express some microglial signature genes, which 24 
is supported by the presence of P2Y12
+
 myeloid populations in the choroid plexus of the fetal 25 
human brain (Mildner et al., 2017). 26 
 In addition to the immunohistochemical reliability of Siglec-H, we addressed the 27 
feasibility of using the Siglech locus for microglia-specific gene manipulation using Siglech
dtr/dtr
 28 
knock-in mice (Figure 6). Genetic targeting of microglia in mice was performed using the gene 29 
loci or promoter/enhancer regions of Itgam (encoding CD11b), Csf1r and Cx3cr1 (Boillee et al., 30 
2006; Jung et al., 2000; Pfrieger & Slezak, 2012; Sasmono et al., 2003). However, given that 31 
these molecules are expressed by a variety of myeloid cells, the effect of the genetic 32 
modification will not necessarily be restricted to microglia (Goldmann et al., 2016; Wieghofer, 33 
Knobeloch, & Prinz, 2015). To circumvent this problem, a new system was established based on 34 
the longevity of microglia (Goldmann et al., 2013; Parkhurst et al., 2013). When Cx3cr1
CreER/+
 35 
mice are crossed to mice harboring a floxed allele, both microglia and peripheral Cx3CR1
+
 cells, 36 
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including monocytes, undergo recombination upon tamoxifen administration. After an interval 1 
of several weeks, microglial recombination persists whereas peripheral Cx3CR1
+
 cells are 2 
replaced by bone marrow-derived progenitors without recombination. Even with this technique, 3 
recombination of mMΦ and pvMΦ can be maintained for a long period together with microglia 4 
because mMΦ and pvMΦ are long-lived cells (Goldmann et al., 2016). Thus finding a 5 
microglia-specific gene locus is considered important. Results from the present cell ablation 6 
study suggest the usefulness of the Siglech locus for microglia-specific targeting in the CNS 7 
(Figure 6a–l and p–r). Another advantage of using the Siglech locus is a lack of recombination 8 
in PNS-infiltrating monocytes (Figure 6j–o). The present results suggest that a Siglech
Cre
 mouse 9 
would be a beneficial tool for future microglial studies. 10 
 A previous study using cultured microglia suggested that Siglec-H was a phagocytic 11 
receptor for glioma cells (Kopatz et al., 2013). This is the only report addressing the role of 12 
Siglec-H in microglia, and Siglec-H functions in the nervous system, especially in vivo, remain 13 
elusive. In the immune system, an anti-inflammatory role of Siglec-H in pDCs has been 14 
proposed (Blasius et al., 2006; Puttur et al., 2013; Takagi et al., 2016; Takagi et al., 2011). 15 
Therefore, we tested the possibility that Siglec-H also suppressed pro-inflammatory responses 16 
of microglia using a mouse neuropathic pain model (Tsuda, 2016). We found that Siglech 17 
knock-down promoted induction of representative pro-inflammatory cytokines in spinal 18 
microglia (Figure 7k) without affecting microglial proliferation (Figure 7l–n). We further 19 
revealed that pain behavior was exacerbated in Siglech knock-down mice (Figure 7o,p). Taken 20 
together, Siglec-H-mediated signals appeared to act as a suppressor of pro-inflammatory 21 
responses in activated microglia. Siglec-H is proposed to be a cell surface receptor, although 22 
ligand(s) remain unidentified (Blasius et al., 2006; Kopatz et al., 2013; Zhang et al., 2006). The 23 
intracellular domain of Siglec-H is very short and Siglec-H is known to form a complex with a 24 
transmembrane adaptor protein, DNAX-activating protein of 12 kDa (DAP12), to induce 25 
intracellular signals (Blasius et al., 2006). In parallel with Siglec-H, other transmembrane 26 
receptors with short intracellular domains, such as triggering receptor expressed on myeloid 27 
cells 2 (TREM2), also bind to DAP12 for signal-transduction (Bouchon, Hernandez-Munain, 28 
Cella, & Colonna, 2001). We recently revealed that TREM2-mediated signals promoted 29 
pro-inflammatory responses of microglia via DAP12 in the ipsilateral dorsal horn and 30 
exacerbated neuropathic pain (Kobayashi et al., 2016). Both Siglec-H and TREM2 are able to 31 
make complexes with DAP12 on microglial surfaces. However, TREM2 promotes inflammation 32 
whereas Siglec-H suppresses inflammation. This controversy is also reported in the immune 33 
system (Blasius & Colonna, 2006; Linnartz-Gerlach, Kopatz, & Neumann, 2014; Turnbull & 34 
Colonna, 2007). Siglec-H and TREM2 are likely to work as an opposing switch for microglial 35 
activation via DAP12. Besides neuropathic pain, TREM2/DAP12-mediated microglial 36 
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activation is also pivotal for pathogenesis of Alzheimer’s disease both in humans and in mouse 1 
models of the disease (Guerreiro et al., 2013; Jonsson et al., 2013; Paloneva et al., 2000; 2 
Paloneva et al., 2002; Wang et al., 2015; Zhang et al., 2013). Therefore, further studies, such as 3 
identification of Siglec-H ligand(s), are needed to reveal the precise molecular mechanisms 4 
regulating microglial activity via DAP12. 5 
 In conclusion, Siglec-H, together with TMEM119, Sall1 and P2Y12, will be useful as 6 
“contemporary” markers of mouse microglia throughout developmental, adult and aging stages, 7 
in both healthy and injury conditions. 8 
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Figure legends 1 
FIGURE 1. Immunohistochemical specificity of Siglec-H antibody in mice. 2 
(a–i) Antigen absorption test using recombinant Fc protein (a–c), Siglec-H-Fc (d–f) and 3 
Siglec-E-Fc (g–i). Immunoreactivity for Siglec-H (a,d,g, green) and Iba1 (b,e,h, red) in the 4 
cerebral cortex and the merged images (c,f,i) are shown. Images were acquired using the same 5 
laser power and sensitivity, and image processing were the same for Fc-, Siglec-H-Fc- and 6 
Siglec-E-Fc-reacted samples (a–c vs. d–f vs. g–i). (j–o) Immunoreactivity for Siglec-H in the 7 
cerebral cortex of WT (j–l) and Siglechdtr/dtr (m–o) mice. Immunoreactivity for Siglec-H (j,m, 8 
green) and Iba1 (k,n, red) in the cerebral cortex and the merged images (l,o) are shown. Images 9 
were acquired using the same laser power and sensitivity, and image processing were the same 10 
for WT and Siglech
dtr/dtr
 samples (j–l vs. m–o). Scale bar:  50 µm. 11 
 12 
FIGURE 2. Siglec-H is expressed by microglia but not by CNS-associated MΦ in adult 13 
mice, except for in the choroid plexus. 14 
(a–d) Siglec-H expression in the surface region of the cerebral cortex. Immunoreactivity for 15 
Siglec-H (a, green) and CD206 (b, red), and the merged image of Siglec-H and CD206 (c) are 16 
shown. Meninges and vessels are visualized by laminin immunostaining (d, cyan). Microglia 17 
(arrows), pvMΦ (single arrowheads) and mMΦ (double arrowheads) are indicated. (e–h) 18 
Siglec-H expression in the surface region of the cerebral cortex. Immunoreactivity for Siglec-H 19 
(e, green) and CD206 (f, red), and the merged image of Siglec-H and CD206 (g) are shown. 20 
Iba1 immunostaining visualizes all myeloid cells (h, cyan). Microglia (arrows), pvMΦ (single 21 
arrowheads) and mMΦ (double arrowheads) are indicated. (i–l) Siglec-H expression in the area 22 
postrema of the medulla. Immunoreactivity for Siglec-H (i, green), CD206 (j, red) and Iba1 (l, 23 
cyan), and the merged image of Siglec-H and CD206 (k) are shown. Insets show higher 24 
magnification images of microglia (arrows) and cvoMΦ (arrowheads). An asterisk indicates a 25 
minor population that simultaneously expresses Siglec-H and CD206. (m–p) Siglec-H 26 
expression in the choroid plexus. Immunoreactivity for Siglec-H (m, green), CD206 (n, red) and 27 
Iba1 (p, cyan), and the merged image of Siglec-H and CD206 (o) are shown. Siglec-H
+
/CD206
–
 28 
(arrows), Siglec-H–/CD206+ (arrowheads) and Siglec-H+/CD206+ (asterisks) cells are indicated. 29 
Scale bar:  50 µm, 15 µm (insets). 30 
 31 
FIGURE 3. Siglec-H is expressed by microglia in the developing CNS of mice. 32 
A, Developmental expression profile of mRNAs encoding Siglec-H and Iba1. mRNA levels in 33 
the cerebral cortex were analyzed by qPCR at each time point (n = 3 for each time point). 34 
Results are normalized to Gapdh, and shown as ratios to 8W mice. Values show the mean ± 35 
S.E.M. (b–g) Siglec-H expression in the developing cerebral cortex at E17 (b–d) and P7 (e–g). 36 
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Immunoreactivity for Siglec-H (b,e, green) and Iba1 (c,f, red), and the merged images (d,g) are 1 
shown. Scale bar:  50 µm. (h) Siglec-H
+
 rate (%) of Iba1
+
 cells in the cerebral cortex beneath the 2 
meninges at E17, P0 and P7 (n = 4; nine images per animal). Values show the mean ± S.E.M. 3 
 4 
FIGURE 4. Siglec-H expression is absent from most infiltrating monocytes in the injured 5 
or inflamed CNS of mice. 6 
(a–h) Siglec-H expression in the optic nerve of Ccr2RFP/+ mice 7 days after crush injury. 7 
Siglec-H immunoreactivity (a,e, green) and RFP signal (b,f, red), the merged images of 8 
Siglec-H and RFP (c,g), and Iba1 immunoreactivity (d,h, cyan) of control (a–d) and injured (e–9 
h) nerves are shown. Insets show higher magnification images of the injury site. Images were 10 
acquired using the same laser power and sensitivity, and image processing were the same for 11 
control and injured nerves (a–d vs. e–h). (i–p) Siglec-H expression in the ventral white matter of 12 
the spinal cord of Ccr2RFP/+ mice with EAE. Siglec-H immunoreactivity (i,m, green), RFP signal 13 
(j,n, red), the merged images of Siglec-H and RFP (k,o), and Iba1 immunoreactivity (l,p, cyan) 14 
of control (naive: i–l) and EAE (m–p) mice are shown. Insets show higher magnification images. 15 
An asterisk indicates a minor population that simultaneously expresses Siglec-H and RFP. 16 
Images were acquired using the same laser power and sensitivity, and image processing were 17 
the same for naive and EAE mice (i–l vs. m–p). Scale bar:  50 µm, 10 µm (insets). 18 
 19 
FIGURE 5. Siglec-H expression is absent from infiltrating monocytes in the injured PNS 20 
of mice. 21 
(a–i) Siglec-H expression in the spinal cord (a–f) and in the distal part of the injured nerve (g–i) 22 
7 days after sciatic nerve transection. Areas indicated by white squares in low magnification 23 
images (a–c) are shown as higher magnification images (d–f). Immunoreactivity for Siglec-H 24 
(a,d,g, green) and Iba1 (b,e,h, red), and the merged images (c,f,i) are shown. Images were 25 
acquired using the same laser power and sensitivity, and image processing were the same for 26 
dorsal horn and sciatic nerve samples (d–f vs. g–i). (j) Expression changes of mRNAs encoding 27 
Siglec-H and Iba1 in the dorsal horn 7 days after sciatic nerve transection (n = 3). The 28 
contralateral (contra) and ipsilateral (ipsi) dorsal horns were subjected to qPCR. Results are 29 
normalized to Gapdh, and shown as ratios to the contralateral side. Values show the mean ± 30 
S.E.M. (k) Expression changes of mRNAs encoding Siglec-H and Iba1 in the sciatic nerve 7 31 
days after transection (n = 3). The contralateral (contra) and ipsilateral (ipsi) sciatic nerves were 32 
subjected to qPCR. Results are normalized to Gapdh, and shown as ratios to the contralateral 33 
side. Values show the mean ± S.E.M. *p < 0.005 and **p < 5.0 × 10
-4
 for upregulation, 
#
p < 34 
0.05 for downregulation; unpaired Student’s t-test. 35 
 36 
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FIGURE 6. DT administration specifically ablates microglia in Siglech
dtr/dtr
 mice. 1 
(a–i) DT induces microglial ablation in the cerebral cortex (a–e) and the area postrema (area 2 
surrounded by dotted line, f–i) of non-injured adult Siglech
dtr/dtr
 mice 2 days after administration. 3 
Merged images of Iba1 (green) and CD206 (red) immunostaining of PBS- (a,f) and DT- (b,g) 4 
treated mice are shown. The numbers of Iba1+/CD206– microglia (c,h), CD206+ pvMΦ (d), 5 
CD206+ mMΦ (e) and CD206+ cvoMΦ (i) are quantified (n = 3; four images per animal). (j–l) 6 
DT induces microglial ablation in the dorsal horn of sciatic nerve-injured adult Siglechdtr/dtr mice 7 
2 days after administration. Merged images of Iba1 (green) and PKCγ (red) immunostaining of 8 
PBS- (j) and DT- (k) treated mice are shown. Lamina I/IIo is surrounded by a dotted line. Iba1
+
 9 
microglial numbers in lamina I/IIo of contralateral (contra) and ipsilateral (ipsi) dorsal horn are 10 
quantified (l) (n = 3; four images per animal). (m–o) DT does not affect the number of 11 
monocytes/MΦ accumulated in injured sciatic nerve of adult Siglech
dtr/dtr
 mice 2 days after 12 
administration. Monocytes/MΦ are stained with anti-Iba1 antibody (green) in the ipsilateral 13 
sciatic nerve of PBS- (m) and DT- (n) treated Siglechdtr/dtr mice. Iba1+ areas of contralateral 14 
(contra) and ipsilateral (ipsi) sciatic nerve were quantified from images taken with the same 15 
laser power and microscope sensitivity (o) (n = 3; four images per animal). Values are 16 
normalized to the whole area, and are shown as ratios to the contralateral nerve of the 17 
PBS-administrated group. (p–r) DT induces microglial ablation in the cerebral cortex of P7 18 
Siglech
dtr/dtr
 mice 2 days after administration. Merged images of Iba1 (green) and laminin (red) 19 
immunostaining of PBS- (p) and DT- (q) treated mice are shown. Putative pvMΦ (single 20 
arrowheads) and mMΦ (double arrowheads) are indicated. The number of Iba1+ cells in the 21 
cerebral cortex beneath the meninges is quantified (r) (n = 3; four images per animal). Scale 22 
bar:  200 µm (a,b,f,g,j,k,m,n), 50 µm (p,q). *p < 0.001, **p < 1.0 × 10-4; unpaired Student’s 23 
t-test. 24 
 25 
FIGURE 7. Siglec-H suppresses pro-inflammatory responses of microglia in a mouse 26 
neuropathic pain model. 27 
(a) Expression profile of mRNA encoding Siglec-H in the dorsal horn. Ipsilateral dorsal horn 28 
was obtained from WT and Siglechdtr/dtr mice at each time point after L4 nerve transection, and 29 
mRNA expression was analyzed by qPCR (n = 3 for each time point). Results are normalized to 30 
Gapdh, and are shown as ratios to the non-operated (naive) value of WT mice. Values show the 31 
mean ± S.E.M. *p < 0.05, **p < 0.005; unpaired Student’s t-test. (b–j) Expression of Siglec-H 32 
protein in the ipsilateral dorsal horn 3 days after L4 nerve injury. Immunoreactivity for Siglec-H 33 
(b,e,h, green) and Iba1 (c,f,i, red), and the merged images (d,g,j) of WT (b–g) and Siglech
dtr/dtr
 34 
(h–j) mice are shown. Higher magnification images of WT mice (e–g, high mag.) demonstrate 35 
Siglec-H expression in microglia. Note that faint signals for Siglec-H are predominantly 36 
Page 31 of 41
John Wiley & Sons, Inc.
GLIA
 32 
observed in the endoplasmic reticulum/Golgi apparatus of microglia in Siglech
dtr/dtr
 mice (arrows 1 
in h–j, high mag.). Images were acquired using the same laser power and sensitivity, and image 2 
processing were the same for WT and Siglech
dtr/dtr
 mice (e–g vs. h–j). Scale bar:  200 µm (b–d), 3 
10 µm (e–j). (k) Expression of mRNA encoding pro-inflammatory cytokines (TNF-α and IL-1β) 4 
but not anti-inflammatory cytokines (IL-10 and TGF-β1) was upregulated in the ipsilateral 5 
dorsal horn of Siglechdtr/dtr mice. Ipsilateral L4 dorsal horn was obtained from WT and 6 
Siglechdtr/dtr mice at each time point after L4 nerve transection (n = 3 for each time point), and 7 
mRNA expression was analyzed by qPCR. Results are normalized to Gapdh, and are shown as 8 
ratios to the non-operated (naive) value of WT mice. Values show the mean ± S.E.M. *p < 0.05, 9 
**p < 5.0 × 10
-4
; unpaired Student’s t-test. (l–n) Microglial numbers in lamina I/IIo were 10 
unchanged between WT and Siglech
dtr/dtr
 mice 7 days after injury. Merged images of Iba1 11 
(green) and PKCγ (red) immunostaining of WT (l) and Siglech
dtr/dtr
 (m) mice are shown. The 12 
lamina I/IIo is surrounded by dotted lines. Scale bar:  200 µm. Microglial numbers in lamina 13 
I/IIo of contralateral (contra) and ipsilateral (ipsi) L4 dorsal horn were counted at 7d (n) (n = 4; 14 
four images per animal). (o,p) Nerve injury-induced mechanical allodynia is exacerbated in 15 
Siglechdtr/dtr mice. The PWT of the contralateral (o) and ipsilateral (p) side was measured in WT 16 
and Siglech
dtr/dtr
 mice (n = 4). *p < 0.05; two-way ANOVA with post hoc Bonferroni test. 17 
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FIGURE S1. Siglec-H is expressed by microglia throughout the CNS of adult mice. 
(a–c) Siglec-H expression in the CA1 region of the hippocampus. Immunoreactivity for 
Siglec-H (a, green) and Iba1 (b, red), and the merged image (c) are shown. (d–f) Siglec-H 
expression in the corpus callosum. Immunoreactivity for Siglec-H (d, green) and Iba1 (e, red), 
and the merged image (f) are shown. Scale bar: 50 µm. (g) Siglec-H+ rate (%) of Iba1+ 
parenchymal microglia in indicated regions of the CNS (n = 4; nine images per animal). Values 
show the mean ± S.E.M. 
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